141 results about "Nasal administration" patented technology

Pharmaceutical formulations of novel indole compounds and psilocybin analogs are manufactured, provided in novel oral, transdermal, and nasal pharmaceutical compositions for use to treat neurological, mood or abuse diseases and disorders.

The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.

Devices, systems, and methods for treating chronic rhinosinutisits (CRS) are described herein. The devices can have a guide member defining at least one lumen therethrough. A drug delivery component is advanced through the lumen to deliver a substance to the sino-nasal cavity of a patient. Once the drug delivery component is positioned at the desired area in the sino-nasal cavity, a user actuates the system to deliver the substance to the target area. Actuation of the system delivers the substance to the middle meatus, osteo-meatal complex, or other areas within the sino-nasal cavity of the patient.

The invention provides application of tea extracellular vesicles in preparation of drugs for relieving or treating allergic respiratory diseases, and belongs to the technical field of extracellular vesicles. The invention provides application of tea extracellular vesicles in preparation of drugs for relieving or treating allergic respiratory diseases. The tea extracellular vesicles are proved to be capable of remarkably improving related symptoms of allergic respiratory diseases including allergic rhinitis, have good anti-inflammatory and immunoregulation effects, and have the application potential of being used as natural active ingredients for preparing drugs or nasal delivery preparations for treating the allergic respiratory diseases. Compared with existing hormone drugs, the tea extracellular vesicles have the advantages of being natural in source, high in safety, low in side effect and the like; moreover, the extracellular vesicles have nanoscale particle sizes, good mucous membrane permeability and bioavailability, can improve the curative effect, and are suitable for long-term intervention.

The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.

Pharmaceutical formulations of novel indole compounds and psilocybin analogs are manufactured, provided in novel oral, transdermal, and nasal pharmaceutical compositions for use to treat neurological, mood or abuse diseases and disorders.

The invention provides a nasal delivery preparation for cerebral diseases as well as a preparation method and application of the nasal delivery preparation, and relates to the technical field of pharmaceutical preparations. The nasal delivery preparation for the cerebral diseases comprises gelatin derivative chitosan microspheres coated with stem cell exosomes, and the microspheres are prepared through the method that the stem cell exosomes are coated with gelatin derivatives of a specific structure and then cross-linked with chitosan. The gelatin derivative used in the invention has good surface activity, and can be well compatible with cells and active factors to form a stable inner core coating structure; meanwhile, the surface of the chitosan of which the outer layer is crosslinked with the gelatin derivative is positively charged and can be combined with anions in nasal mucus, so that the retention time of the microspheres in the nasal cavity can be effectively prolonged. Therefore, the nasal delivery preparation not only can slowly release the stem cell exosome, but also improves the absorption efficiency of the stem cell exosome by the nasal cavity, so that the stem cell exosome can reach the brain more effectively.

Devices, systems, and methods for treating chronic rhinosinutisits (CRS) are described herein. The devices can have a guide member defining at least one lumen therethrough. A drug delivery component is advanced through the lumen to deliver a substance to the sino-nasal cavity of a patient. Once the drug delivery component is positioned at the desired area in the sino-nasal cavity, a user actuates the system to deliver the substance to the target area. Actuation of the system delivers the substance to the middle meatus, osteo-meatal complex, or other areas within the sino-nasal cavity of the patient.

The invention relates to the technical field of exosome preparations, and particularly discloses an exosome nasal delivery preparation as well as a preparation method and application thereof. The preparation comprises the following components: 1 * 10 < 9 >-5 * 10 < 11 > particle number / ml of exosome, 1%-4% w / v of a saccharide protective agent, 0.5%-4.5% w / v of an alcohol protective agent, 0.05%-1% w / v of an absorption enhancer and a solvent. The exosome nasal delivery preparation can break through the blood brain barrier and quickly take effect, and the intracerebral delivery efficiency of the exosome nasal delivery preparation can be improved by 2-5 times compared with intravenous injection. The nasal administration preparation can be used for treating central nervous system diseases such as cerebral apoplexy and the like, and can remarkably improve the neurological function, reduce the cerebral infarction area and promote functional recovery.

The present disclosure provides a nasal delivery device with a device body that includes a trigger end and an outlet end. The nasal delivery device also includes a trigger assembly coupled to the trigger end of the device body, a drug container supported by the device body, and a spring-loaded activator assembly supported by the device body and disposed between the trigger assembly and the drug container.

Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.

1. The name of the design product: single dose nasal administration device. 2. The use of the design product: the design is mainly used in single dose nasal inhalation administration device. 3. The design points of the design product: in the design 1 perspective view. 4. The picture or photo that best indicates the design points: design 1 perspective view. 5. Design 1 is designated as the basic design.

The invention belongs to the technical field of pharmaceutical preparations, and provides a novel solution type nasal administration composition of quetiapine. In the provided composition, quetiapine is completely dissolved in the composition in the form of a solution, and is administered via the nose. The quetiapine solution type nasal preparation provided by the invention has especially useful pharmacokinetic and pharmacodynamic characteristics compared with oral dosage forms on the market. Compared with other disclosed nasal nano-emulsion forms, the nasal nano-emulsion still has surprising pharmacokinetic and pharmacodynamic characteristics, shows good clinical application prospects, and is expected to meet unsatisfied clinical requirements. On the basis, the invention also provides a further improved technical scheme of high saturated dissolution concentration and a further improved technical scheme of good chemical stability for preparing the quetiapine solution type nasal preparation.

The invention provides a compound comprising one, two, three or more non-natural HRC sequence of a viral spike peptide conjugated to a hydrophobic moiety via an optional linker. The hydrophobic moiety can be a membrane integrating ligand, such as a cholesterol, a sphingolipid, a glycolipid, a glycerophospholipid. The non-natural viral spike peptide is preferably a coronavirus spike protein characterized by one or more D-amino acids. The peptides of the invention inhibit viral fusion. The invention includes compositions for the delivery of compounds of the invention, such as pulmonary or nasal delivery. The invention also provides a method of treating or preventing a viral infection, including for example a SARS-CoV-2 (COVID-19) infection, in a subject in need thereof comprising administering an effective amount of a compound of the invention.

The invention discloses a construction method of a human-derived HMC3 microglial cell line modified strain (named SIRT2-KD HMC3) for treating Alzheimer's disease (AD). The cell strain is obtained by knocking down an SIRT2 gene through genetic engineering. The invention also discloses a method for producing LEVs by using the cell strain, the cell strain can form an M2 anti-inflammatory form in a culture process, and the microvesicles LEVs-sh-SIRT2 are obtained by collecting a culture solution and adopting an ultra-high speed centrifugation method. A preclinical animal test (AD mode mouse APP / PS1) result shows that the LEVs prepared by the invention can effectively regulate and control inflammatory response and promote phagocytosis. After nasal administration, the LEVs can smoothly penetrate through a blood brain barrier to enter a hippocampus and are taken by microglial cells, so that chemotactic and phagocytic activities of the microglial cells are promoted, deposition of A beta in the brain is reduced, cognitive impairment of experimental animals is remarkably improved, and the medicine has a wide application prospect in the field of AD innovative treatment.

A nasal pharmaceutical composition comprising a porous excipient and an active agent, wherein the active agent is loaded onto a surface of the porous excipient located within pores of the porous excipient, wherein the porous excipient is an inorganic porous material selected from colloidal silicon dioxide, mesoporous silica, microporous silica and macroporous silica, and wherein the loaded porous excipient is dispersed in a gel, the gel comprising a vehicle comprising an oil or a mixture of oils, and wherein the composition is designed for nasal administration.

1. The name of the design product: nasal cavity administration atomization device (without dust cover). 2. The use of the design product: the design product is used to spray the atomized medicine to the nasal cavity olfactory region. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view 2.

The present application relates to the technical field of nasal administration, and more particularly to an ultrasound-enhanced olfactory mucosa brain-targeted infusion probe, system and method, wherein the probe comprises a probe catheter, an ultrasound activation module capable of enhancing the permeability of the olfactory mucosa of a patient, and a fit degree module capable of obtaining the size of the fit between the probe catheter and the lateral wall of the nasal cavity of the patient, the ultrasound activation module and the fit degree module are both installed on the lateral wall of the probe catheter, the ultrasound activation module and the fit degree module are connected with a control module through a wire bundle arranged on the inner lateral wall of the probe catheter, and the administration channel in the lumen of the probe catheter is in communication with the outside of the probe catheter through an administration port. The scheme of the present application can obtain the fit between the probe catheter and the lateral wall of the nasal cavity after the probe catheter is inserted into the nasal cavity, so as to facilitate the doctor to timely adjust the position of the probe catheter when the fit does not meet the working conditions of the probe catheter, and successfully fit the probe catheter to the specified position of the lateral wall of the nasal cavity.

A discharge head for nasal application of liquid from a pressure reservoir (110) is known. In order to be able to produce such a discharge head in a cost-effective manner, some measures are proposed. In particular, for this purpose, a discharge head (10) is proposed which has a base unit (20) with a coupling device (24), by means of which the discharge head (10) can be fastened to a pressure reservoir (110). The discharge head (10) has an actuation unit (50) with an elongate nasal applicator (60) extending along an applicator axis (4) and an actuation surface (70), and which is mounted on a base unit (20) in a pivotable manner about a pivot axis (6) by means of a hinge device (30, 90), such that for the purpose of opening an outlet valve (112) of a pressure reservoir (110), the actuation surface (70) is attached to the outlet valve (112) of the pressure reservoir (110). The actuation unit (50) can be pressed down in a pivot actuation direction. In particular, the components (22, 52) of the discharge head are produced by means of an injection mould that can be separated along an axis.

A plug (1) for insertion into the nose or ear of a subject, comprising: a body (10) adapted to fit into a nostril (2) or ear canal (3) of the subject and a tubular member (20) with a collar (25) disposed substantially inside the body. The plug is adapted to receive a tip of a syringe (30) for injection of a fluid therapeutic agent through the tubular member for nasal administration or administration to the ear. A kit comprising the plug and a syringe, as well as a method for administering a fluid therapeutic agent to a subject using the plug are also disclosed.

The present disclosure relates to compositions for the restoration of porosome faction, comprising isolated porosome complexes that include a functional CFTR protein and a pharmaceutically acceptable excipient. These compositions are specifically formulated for inhaled or nasal administration, enabling delivery of the functional porosome complexes directly to the airway epithelium. By restoring the presence of functional CFTR within the porosome complex at the plasma membrane, the disclosed compositions address the underlying secretory defect in cystic fibrosis and provide a novel therapeutic approach for patients affected by this disease.

The invention relates to a device for the nasal dispensing of a fluid or powdered product, the device comprising a dispensing head (10) that is provided with a dispensing opening (11) and is suitable for being at least partially inserted into a nostril during actuation, the dispensing head (10) being mounted on a reservoir (30) containing the fluid or powdered product to be dispensed, a dispensing member (20) being provided to dispense the product contained in the reservoir (30) in a dosed manner, the device comprising an end piece (40) arranged around the dispensing head (10) and comprising a bearing surface (41) which, in use, is designed to rest on the entrance of a nostril, and a finger-rest surface (45) for accommodating the fingers of a user when the device is being used, the finger-rest surface (45) curving upward, so as to form an upwardly curved cylindrical section that extends radially on either side of the dispensing head (10).

The invention discloses a lipophilic modified nucleic acid medicine composition and application thereof, the lipophilic modification is saturated or unsaturated C4-C30 alkyl, the composition comprises an absorption enhancer, and the method is that the lipophilic modified nucleic acid medicine is delivered to the brain through the nasal mucosa. Nucleic acid drugs are transmitted into the olfactory bulb region through a neural pathway, namely, cross-olfactory mucosa, bypass BBB and directly enter the brain, the drug concentration content of the olfactory bulb is far higher than that of other tissues of the brain, and the tissues except the olfactory bulb are uniformly distributed, so that the olfactory bulb can be used as a drug reservoir and gradually and slowly spread to the other tissues of the brain; the long-time drug effect can be maintained by one-time drug administration, so that the drug administration frequency can be reduced. Compared with intrathecal injection, by adopting the composition disclosed by the invention for nasal administration and using 1 / 2 of intrathecal administration dosage, the same intrathecal steady-state distribution as intrathecal distribution can be achieved, so that the method disclosed by the invention is safer, noninvasive and efficient.

The present invention concerns novel use of adrenaline for improving the treatment of shocks, comprising the intra-nasal administration of compositions of adrenaline.

1. The name of the design product: spray pump (without cap). 2. The use of the design product: the design product is used for the medicine nasal administration device. 3. The design points of the design product: in shape. 4. The picture or photo that can best show the design points: perspective view.

The invention discloses a preparation method and application of a nasal administration compound preparation for relieving the drug resistance of cisplatin, belongs to the field of precision medicine, and particularly relates to the nasal administration compound preparation for relieving the drug resistance of cisplatin. Comprising stem cell exosome, zanthoxylum polysaccharide, cis-platinum and normal saline, the stem cell exosome is a human adipose-derived stem cell exosome; the concentration of the human adipose-derived stem cell exosome is (2-5) * 10 < 7 > parts / mL. The nasal delivery compound preparation for relieving the cisplatin resistance has the advantages that the exosome is low in cytotoxicity and good in anti-tumor activity, the E2F8 / PDK1 axis can be adjusted, the cisplatin resistance of lung adenocarcinoma cells can be weakened, the lung adenocarcinoma cells can be effectively killed, the good lung adenocarcinoma treatment effect of the nasal delivery compound preparation is reflected, and the application prospect is wide. The compound is expected to be applied to development and use of medicines for clinically treating lung adenocarcinoma.

1. The name of the design product: nasal cavity administration atomization device. 2. The use of the design product: the design product is used to spray the drug liquid atomized to the nasal cavity olfactory region. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view 2.

The application discloses a passive micro-fluidic liquid slow-release system and a nasal cavity drug delivery device, which comprises a micro-fluidic liquid storage bin, a multi-stage gradient flow resistance channel network, a slow-release unit and an air inlet and outlet balance assembly. The system makes the equivalent diameter of the micro-channel gradually decrease along the flow direction, concentrates the flow resistance on the end micro-hole, shields the liquid level fluctuation at the front end, and realizes passive constant pressure release. In view of the problems of liquid injection and start, independent air inlet and outlet micro-channels and a detachable elastic gas storage bin are introduced, air is discharged and liquid is sucked under negative pressure during liquid injection, the gas storage bin is pressed to generate a pulse to break a disposable micro-fluidic valve during start, and the air pressure is balanced through the air inlet channel during the release period to prevent vacuum deadlock. Combined with the continuous conical transition and the end biomimetic capillary groove liquid locking design, the application completely gets rid of the constraint of external power, and is suitable for portable nasal cavity essential oil slow-release and clinical micro-dosage.

The present invention relates to a pharmaceutical composition comprising ramelteon and a nasal administration formulation. The pharmaceutical composition comprises ramelteon and polyethylene glycol. The pharmaceutical composition of the present invention has high stability and can be used to prepare a pharmaceutical formulation that meets the specifications for nasal administration formulations. Compared with oral tablets, the pharmaceutical composition of the present invention features improved bioavailability of ramelteon and a targeted concentration in brain tissue.